When glaucoma sufferers started using the eye-drop drug Lumigan eight years ago, who knew there’d be fringe benefits: longer, lusher, darker eyelashes. Eventually, Allergan, the makers of the drug, sped it into clinical trials (this time for hypotrichosis, aka underdeveloped eyelashes), repackaged it, gave it a girly name (Latisse), and marketed it for its lash-boosting magic.

Read full story via sfgate.com